CBD Cannabis Oil Medical Recreational Health

$89 60 Min Full Body CBD Massage & 10 Min Scalp Massage (a $210 value) | The Marianella Soap Bar | spa


Embrace the chill you so desperately need in an environment that encourages comfort, empowerment, and a holistic approach to self-care. The mother and son duo behind The Marianella Soap Bar have used old-school techniques coupled with new advances in wellness to retain a sense of authenticity in a world full of chemical additives and mass-produced nonsense.

The same holds true for their spa service, like the CBD Oil Massage & Scalp Massage, aka 70 minutes of mind-blowing zen as the highly-trained massage therapists work their magic on stubborn knots and tight spots. The utilization of these natural substances in a safe, effective, fast way to achieve maximum results.

Capitalize on your new glow by treating yourself to owner Marianella Febres-Cordero’s handmade spa creations. Inspired by her upbringing in Venezuela, Marianella grew up making soaps in her grandmother’s kitchen and carries on this tradition by handcrafting some onsite in the Thompson Street store.

Make sure to grab Oprah’s favorite soap or say hi to JVN if you are lucky enough to spot him on the way in. Neon signs, live plants, and perfectly organized decor are begging to be shared on your feed.

Best of all, every purchase gives back to a variety of charities that support women’s rights and empowerment. We’re pretty sure that, after a visit to The Marianella Soap Bar, you’ll float away on a puffy white cloud of pure bliss…

Your $89 Massage (a $210 value) Includes:

  • A 60 Minute CBD Massage ($190 Value).
  • A 10 Minute Coconut Oil Scalp Massage ($20 value).

The Marianella Soap Bar’s products and services command 5 stars on Yelp with reviews that include:

  • “The Royal Kalahari Face Serum is the best face serum I have ever used. It dries quickly, evens your skin tone, evens your skins texture, and lasts all day without ever feeling oily…. So glad to have stumbled into this gem while walking my dog in the neighborhood.”

The Marianella Soap Bar’s Website | Yelp



Source link

Va. Businesses Sell CBD Oil Despite Hazy Legality



Cannabidiol, also known as CBD oil, is becoming more and more popular as a way to treat various ailments and help people relax.



Source link

Tulsa Public Schools Proposes New Medical Marijuana Policy



The TPS policy continues the existing ban on recreational marijuana, and creates one for medical marijuana and defines what's permitted for CBD oil …



Source link

How Long Does It Take for CBD to Wear Off?


We do have a strong basis to say that CBD has the potential to be an effective medicine, but how long do its effects actually last?

Cannabidiol is one of the main ingredients in hemp-based CBD oils and a popular alternative medicine. CBD oils can be used for a variety of different illnesses and disorders, with some of its most popular uses being for anxiety, depression, as an anti-inflammatory, for pain relief and as an acne treatment.

Research into CBD oils is still ongoing, but from the current studies, we do have a strong basis to say that CBD certainly has the potential to be an effective medicine. But if you want to use CBD oils, how long will their effects last?

This will actually depend on a number of different factors, and the type of CBD oil you use will play a big part in it. CBD oils are available in numerous different forms including tinctures, creams, capsules, and vapes,  for starters.

Let’s examine each type of CBD oil in more detail, and look at how each is different when it comes to how long it takes to kick in, and how long you will feel the effects for. Some CBD oils can last for as long as 6 hours while others won’t last anywhere near as long. 

CBD Oil Vapes 

Some people are put off by the vaping process, but CBD oil vapes do have the advantage of being very fast acting. They will often get to work in just a few minutes, and can last for a couple of hours. However, the downside to CBD oil vapes is that you won’t intake as much CBD as with other methods, so you might not feel the full effects.

CBD Oil Tinctures and Sprays 

Tinctures and sprays are two of the most popular ways to consume CBD oil, because they’re quick to use and can be easily carried with you. Simple and straightforward, these two methods are also very fasting acting, and the effects are relatively long-lasting. The average dosage will often last about four hours, although it can last as long as six!

CBD Oil Capsules 

Capsules are another popular way to take CBD oil, but there is a lot more variation to how long they can last and how long they take to actually start working. Capsules will work better and your body will absorb it quicker on an empty stomach. CBD oil capsules will usually get to work within 30 minutes, though sometimes it can take up to an hour or more. The effects last for about 6 hours on average.

CBD Oil Topicals 

CBD oil topicals come in many different forms, including creams and lip balms, but how do they actually work? CBD oil topicals are absorbed more slowly through the pores in your skin, which makes them last longer than other CBD consumption methods. They can take longer to work than other methods, although that depends on the type of topical. Sometimes they can take as little as 5 minutes, other times it will take as long as 30 minutes. Topicals can last a long time, though again, it depends on the type.



Source link

The Truth About CBD Oil! Should You Use CBD Oil?



The Truth About CBD Oil! Should You Use CBD Oil? Andrea Jones – The Natural Health School. Loading… Unsubscribe from Andrea Jones – The …



Source link

For Brazil, courting importers is the only way to provide medicinal CBD access


Brazil’s new medical marijuana law, which would allow medical patients to cultivate the plant for personal medical use, is in jeopardy while companies from all over the world attempt to buy a slice of the medical import market, which could become of the biggest in the world.

Brazil has a janus-faced relationship with cannabis. Historically, it has followed the UN’s drug standards, a confiscate and prosecute methodology. Since 2006, the country has slowly deregulated medical cannabis, with a historic medical cultivation bill approved by the Senate in November 2018.

As of January 2019, the bill is in jeopardy due to Brazil’s new president, Jair Bolsonaro, who is staunchly anti-drug, including cannabis. He’s not alone.

[Transforming the CBD marketplace: PotNetwork’s exclusive interview with Youngevity President and CFO Dave Briskie]

The deregulation has done little to change attitudes about cannabis with only about a 2 percent increase in support for recreational marijuana from 1995-2017, according to Datafolha, a Brazilian research group, and has even produced unintended consequences, with more individuals incarcerated for drugs than ever in Brazil’s history.

Medicinal CBD oil has been legal in the country since 2015, and demand for cannabis as medicine has increased. At least four international cannabis firms, GW Pharmaceuticals from the United Kingdom (NASDAQ:GWPH); Khiron Life Sciences, Corp. from Canada (OTCQB:KHRNF) (TSXV:KHRN), Mr. Pink, from China, and the American company Medical Marijuana, Inc. (OTC:MJNA) are entering or positioning to enter the Brazilian market.

CBD Oil supply trying to keep up with demand

In 2015, Brazil legalized CBD oil for medicinal purposes. Today it is one of the top global importers of CBD oil, number 13 in the world.

Brazillian senator Marta Suplicy argued in a letter: “We need to empathize and put ourselves in the place of the other. In this way we can, as legislators, defend the true essence of health care, which is to mitigate human suffering.”

Meanwhile, healthcare regulators in the country require CBD oil to be prescribed by a doctor, but the 2015 law omitted statutes to cultivate and refine plant.

[N.J. governor, state Democrats say deal to legalize cannabis almost done]

The new bill, which would allow medical cultivation, is not expected to pass, but nothing is preventing regulators from courting imports from medicinal CBD companies.

The Brazilian bill

Spotlighting important importers

In January 2017, GW Pharmaceuticals, a cannabis pharmaceutical company, with its partner, a French company with a Brazillian branch, Ipsen Pharmaceutical, Ltd. (OTCMKTS:IPSEY), gained the first license from ANVISA, Brazil’s health regulatory agency. They distribute Sativex, which is designed to moderate symptoms of spasticity.

Soon after, HempMeds Brasil, a subsidiary of Medical Marijuana, Inc., claims the title as the first importer of CBD oil to Brazil. Medical Marijuana, Inc. is an American company seeking to build a global market for CBD. CBD demand is so high in Brazil that the country waived import tariffs for HempMeds. HempMeds is not only importing CBD oil into Brazil, but it’s building a learning community for doctors to build their knowledge about the benefits of CBD as medicine.

Next, we look at two suitors.

Khiron Life Sciences, Corp. is hoping to enter the Brazillian market via partnerships with Uruguayan Nettagrowth International. They are capitalizing on cheap production costs in Brazil’s southern neighbor and the permissive export market between them. When Khiron begins Brazillian imports is not yet clear.

[Marijuana banking finally ranks a congressional hearing]

Finally, Pink Wangsuo, a Chinese entrepreneur, and owner of a premium CBD oil company visited Brazil this week to begin negotiating potential CBD oil imports to the Latin American country. Mr. Wangsuo, best known for his ginseng drink company, launched a CBD oil company in Los Angeles. He wants to not only import CBD to Brazil but also expand Brazil’s internal CBD market via investments and jobs in the industry.

What’s next for Brazil?

With the legal cultivation bill uncertain and demand for CBD on the rise, Brazil needs to make choices regarding the medical cultivation bill and import market.

The landmark bill, to open up medical cultivation for individuals, if passed, poses challenges for individuals isolating pure CBD chemicals from plants. Marcelo De Vita Grecco, CEO, and co-founder of Centro de Excelencia Canabinoide told MJBuisness Daily that, “patients should have access to standardized and safe products, and cultivating at home is too risky [and] also highly inconvenient.”

European Parliament passes resolution to address barriers to medical marijuana access]

With no public discussion regarding industrial-scale cannabis production within the country, if Brazil is to continue to put the needs of their patients first, it will need to continue its partnership and import model.

Lucky for Brazil, and luckier for its patients, there is no shortage of companies hoping to enter the Brazilian market.





Source link

The CBD Oil Debate: Is It Safe For Your Dog?


Brett Hartmann gives his dogs Cayley, a six-year-old-Labrador Retriever drops of a cannabis based medicinal tincture to treat hip pain and anxiety, June 8, 2017 at his home in Los Angeles, California. It's early morning, just after breakfast, and six-year-old Cayley is wide awake, eagerly anticipating her daily dose of cannabis.The black labrador, tail wagging, laps up the liquid tincture owner Brett Hartmann squirts into her mouth, a remedy he uses morning and evening to help alleviate Cayley's anxiety.As the multi-billion dollar medical and recreational marijuana industry for humans blossoms in the United States, so is a new customer base -- animals.

(Picture Credit: ROBYN BECK/AFP/Getty Images)

The benefits of cannabidiol (CBD), or cannabis oil, for dogs have been the subject of recent scrutiny. Some dog owners claims that CBD helps their dogs with a host of medical conditions. Others hear that CBD comes from marijuana plants and immediately become wary of these products.

With the current legalization of marijuana in different states, accidents of pets overdosing on marijuana have made this a touchy subject for pet owners. That’s understandable, even though CBD does not produce the high that comes with other marijuana products and is not responsible for overdoses.

Even if CBD doesn’t have the same negative effects in pets, pet owners should ask whether it’s actually helpful for their furry family members.

If you are wondering whether CBD oil may be the way to your pet’s relief, here are a few things to know about the product.

What Is CBD Oil?

When one hears of cannabidiol, cannabis oil, or simply CBD oil, it’s easy to picture outrage, even with the movement toward legalization of marijuana. Marijuana’s effects on dogs still have to be further studied, but this does not mean CBD oil use should be classified with it.

CBD oil is derived from the cannabis plant. There are different ways to extract oil from the plant, some of which remove all the THC content. THC is the substance in marijuana that brings the feeling of “high.”

The targeted part of the cannabis plant is the flower, which has trichomes filled with essential oils. Marijuana can have up to 80 cannabinoids, which can include either THC or CBD. The psychoactive element is THC, while CBD is mainly used for its medical properties.

The key to using CBD oil safely for dogs is to ensure the right dosage that balances little-to-no THC in the mix. “Depending on the nature of the product, if it contains little or no THC, then the dog is not going to get high,” said Dr. Gary Richter who is also the medical director and owner of the Montclair Veterinary Hospital in California.

Putting The Perk Back In Your Pet


Most older dogs experience pains and anxiety, especially those who are suffering with arthritis and other conditions brought on by old age. There are common medications for this, but they eventually tend to lose effectiveness, which impacts dogs’ quality of life.

This is where some pet owners start to swear by the effects of CBD oil.

CBD oil reduces anxiety in many pets, including separation anxiety and thunder phobia. It can also act as an agent against inflammation, making it a good soothing element for dogs suffering from arthritis.

In some cases, CBD can also be used as a natural ingredient in lieu of phenobarbital. In one such case, Petey, a 5-year-old Beagle, suffered from a prolonged grand mal seizure. Instead of phenobarbital, which can have many side effects, his owner tried CBD oil.

Petey’s condition improved. In three months, he went from one to two big seizures per month to only one small seizure.

The Bottom Line About CBD Oil For Pets

The idea of your pet ingesting marijuana may seem scary, but only if you don’t know the difference between CBD oil and other cannabis products.

Pet owners have to overcome a big misconception about CBD oil. Most people believe that manufacturers create CBD oil products equally. Farming and production processes differ given the lack of regulation.

CBD oil for dogs comes mostly from hemp. The final product includes very little to no THC trace, giving your dog all the benefits with the least potential for risk.

With that in mind, CBD oil is safe for most dogs in the right doses and with the right products. However, you must consult your veterinarian before you give your dog any CBD. Your vet can advise you about your individual dog and give you more information about administering it safely.

You can buy CBD oil as over-the-counter items since they are not considered controlled substances.

Are you considering using CBD oil for your dogs? What’s your biggest concern about the product? Let us know in the comments below!

Related Articles:

Study Shows Dogs Can Detect Malaria Just By Sniffing Socks

Dog Training Program Symbolizes Hope For Florida Inmates





Source link

Deepak Anand on CBD Regulations and European Market Domination


Cannabis business expert Deepak Anand provides an update on his work with cannabis social justice agencies as well as his take on stories shaping the global cannabis industry. Anand works with Norml Canada, an organization working on amnesty for Canadians who have been unfairly charged with cannabis-related offenses as well as CFAMM, a group looking to ensure medical cannabis patients have fair access and taxation. Anand observes that the excitement regarding the health benefits of CBD oil has led to regulatory problems, especially in Europe. However, the US is moving toward a regulated CBD industry and the US FDA is trying to regulate CBD products. In terms of European expansion, Anand believes Canadian LPs have a huge advantage when compared with MSOs. The European market requires EU GMP certification and US MSOs cannot earn this certification without federal legalization. However, Anand cautions that other countries such as Israel, which recently allowed cannabis exports,  are primed to dominant the European space.

Transcript:

Benjamin A. Smith: Welcome back, everybody. On the line joining us is the one and only Deepak Anand. Welcome, Deepak.

Deepak Anand: Thanks for having me.

Benjamin A. Smith: Great. This is the first time we’ve spoken, so the pleasure’s all mine. Now, I wanted to ask you, getting right into it, how are things at your new location at NORML? Do you like working on the policy side of the equation a little bit more than your last gig, or how is that working out for you?

Deepak Anand: Yeah, absolutely, and I’ve always been involved in the policy side, you know, for many, many years. You know, I’ve assisted both Federal as well as provincial governments on cannabis policy, and the role at NORML is just further expanding that anyways.

I mean, one of the biggest things that we’re, you know, sort of moving forward on NORML is the whole amnesty piece, because quite frankly, you know, we’ve gone forward with legalization and, you know, we’ve unrolled a number of things in various provinces. But one of the big issues that still is unresolved is Canadians still continue to be charged unfairly for cannabis-related offenses, and more importantly, there’s a number of Canadians that are sort of, you know, charged historically for minor possession. And you know, one of the things at NORML we’re trying to do is, sort of, you know, fight or lobby for that.

So one of the things that we’re looking to actively sort of lobby for is to ensure that Canadians that have been unfairly charged for cannabis-related offenses are granted amnesty in some end. And you know, there’s that issue that sort of is living, because a number of people, to this day, can’t apply for licenses, they can’t travel to the US – I mean, it’s a serious issue.

Benjamin A. Smith: Okay. Can you tell me what is the motivation or the backers behind the criminality of cannabis infractions, if you want to call it? Is it just sort of a public service that people are trying to get, you know, people not charged under cannabis laws or predatory cannabis laws? Or is there a real backer behind it? What is the motivation behind that, or is it just sort of a policy think-tank thing?

Deepak Anand: Yeah, I mean, you know, historically we’ve had laws in this country that would prohibit anyone from sort of undertaking cannabis retail businesses. And a lot of the laws, you know, whilst the Cannabis Act may have come into effect, a number of laws relating to amnesty and particularly simple possession charge under the previous regulations still hold. I mean, one of the things that the Liberal government said when they were legalizing cannabis was, you know, they would look at sort of cannabis amnesty once they’ve dealt with legalization.

Now that the legalization file has unraveled, you know, we very much are proud of working with them to make sure that we hold their feet to the fire as far as cannabis amnesty is concerned.

Benjamin A. Smith: Sounds good. Now, switching gears to CBD oil: there’s been a lot of talk about all the therapeutic benefits, and of course, there are plenty. It’s, you know, anti-inflammatory, it helps you sleep, there’s a lot of good attributes to it.

Now, I want to get your thoughts about whether you think CBD oil ultimately is a little bit of a fad, or do you think it will, you know, eventually exceed expectations about the therapeutic aspects that it can bring to patients?

Deepak Anand: I mean, clearly there are, you know, a number of benefits with CBD; you know, there’s a number of clinical evidence currently being formed around CBD in a variety of different conditions, and whilst it may be beneficial for certain conditions, I think that we’re getting ahead of ourselves in many ways. If you look at what’s happening in the UK, for example, I just got back yesterday, and there’s CBD everything in a whole bunch of High Street stores or pharmacies that are available over the counter, whilst, you know, the product in general remains unregulated.

Germany is the same story, and now we’re seeing the US, you know, look to put some of the toothpaste back in the tube. I think there are benefits for CBD, clearly, for some conditions, but I think we’re getting ahead of ourselves here by just producing a whole bunch of CBD products. And I think if you look at the Canadian perspective, I think we’re doing it right. We are looking to regulate both THC and CBD in terms of how it can be used, whether that be CBD water, whether that be CBD in vitamins, etcetera.

I mean, quite frankly we don’t know all of the details around CBD at this point. Whilst it may have therapeutic sort of potential for some, it’s not this miracle hail-all drug that people seem to be making it out to be.

Benjamin A. Smith: Okay. When do you expect the regulation behind the manufacturing and safety profile of CBD is going to be generalized within the industry? Because as you mentioned, there’s a lot of unregulated CBD out there, a lot of it that there’s not that regulation framework to really help it. How long do you expect that to catch up? Is it going to happen, you know, now that the Farm Bill has passed, is it going to happen within, say, 12 to 24 months?

Deepak Anand: Yeah, absolutely. I mean, the US FDA has clearly said that they’re going to look at sort of, you know, regulating CBD. We’ve seen a number of states move forward now and actually take CBD off shelves completely, not allowing dispensaries or retail stores to, you know, even carry CBD. So whilst I think the US needs to do a number of things from a Federal legality standpoint, I think that, you know, the latest move with the Farm Bill and getting the US FDA involved clearly shows that this is going to be a regulated industry.

It’s going to be something that is very near to the US. I mean, whilst it had a number of different products around for very many years, including CBD products, at the same time, the times change, and I think a number of these companies are going to have to get into compliance from a regulatory perspective. And I think that’s predominantly what the United States Food and Drug Administration is looking at, you know, is making sure that anything that’s currently on the shelves is safe for human consumption.

Because quite frankly, for too long, the product’s been unregulated, untested, and by and large, unsafe, you know, potentially full of, you know, pesticides and other heavy metals, etcetera. There was a study that was just done yesterday that looked at six CBD products on the market and either found no CBD in it, or found dangerously high levels of pesticides and other sort of harmful ingredients in the product. So that is going to have to change, and I think that’s predominantly what the US FDA is looking to do at this point.

Ed Milewski:  Deepak, your company is a Canadian company, is that correct?

Deepak Anand: Yes, that’s correct. I sit on the Board of a number of different organizations; I think what we were talking about earlier was an organization called NORML. NORML is a worldwide organization in the stance for sort of, you know, the organization for marijuana laws and reform against sort of unjust laws. One of the other, you know, organizations that I sit on the Board of is called CFAM, and that’s Canadians for Fair Access to Medical Cannabis, and I think you’ll hear a lot this week in terms of some of the initiatives that we’re working on, to eliminate tax from medical cannabis.

These are non for profit entities that I sit on the Board of.

Ed Milewski:  You’re talking to other countries all the time, I guess, and looking at different approaches, different ways to sort of have a unified view of, you know, how this should be handled so that there’s not a lot of differences between countries.

Deepak Anand: Yes, absolutely. One of the things that I’ve been doing is working very closely with a number of different Federal governments, as a policy advisor, to kind of assist them in understanding sort of all of the implications of this. And I mean, the fact that, you know, we as Canada have been sort of the second nation and really the first G7 nation to legalize both THC and CBD in medical cannabis and non-medical cannabis in general, I think there is a number of lessons to be learned here, and I think that’s what we’re, when talking to new countries, that’s one of the things that sort of, you know, I advise them, is let’s not make the same mistakes that Canada has made.

I think there’s a lot to be learned from the Canada experiment, as I would call it, but there’s also some opportunities to create some new frameworks. And each of these countries has their own unique challenges, and they need to work within it. So that’s the interesting part.

Whilst all this is happening, I mean, you know, the whole United Nations just released a report, you know, by the WHO, which is the World Health Organization, that sort of called for complete de-classification or deregulation of CBD and removing it from any treaties.

So there’s, you know, a whole bunch of other things that are happening internationally on this pile that seem to be moving almost daily, and we’re seeing more and more countries, you know, daily almost, look at legalizing medical cannabis, so it’s quite exciting from that front.

Ed Milewski:  Sure.

Benjamin A. Smith: Okay, Deepak, I know the capital markets perhaps isn’t your primary focus, but I wanted to get your thoughts about the Canadian LP advantage, especially on the Tier One side, the Canopies, Aphrias and so forth. Now, there’s a line of thinking out there that believes that the Tier One Canadian LPs have a decided advantage internationally, because they’ve already set up shop, they have a different agreements in other countries like Germany, the UK and Latin America, as opposed to the multi-state operators down in America.

So do you consider this a big head start and a big advantage that the Canadian LPs on the capital markets side can parlay into against their MSO neighbours down south, who aren’t even really established internationally?

Deepak Anand: Yeah, absolutely. I mean, if you look at predominantly the European market, I mean, it is a medical cannabis market currently if you look at Germany, you look at the UK, you look at Greece, you look at, you know, a number of other European countries, they’re all currently going down or have gone down the medical path. And they require something called GMP, which is Good Manufacturing Practices; really only six companies in Canada currently have it. There’s a couple more that are currently going through the process, but it is a difficult process to go under, and I mean, it’s taken these six LPs that currently have this, a great deal of time to be able to get this GMP certification. It’s a higher quality sort of, you know, of a quality management system than the ACMPR regulations under which a majority of the Canadian Licensed Producers currently operate.

That program is called something at GPP, Good Production Practices, and then Good Manufacturing Practices is something that pharma companies follow. So really, these six companies have a global opportunity at the moment to be able to dominate the landscape, and they certainly are; we’re seeing a number of countries already start to export to Germany. I think this week we’ve seen, you know, today Aurora announced their first shipment to the UK; last week Canopy made a similar announcement. When you compare that, you know, to the US, I mean, you know, your question around, will we face sort of threat from the US?

I think that a number of US multi-state operators or MSOs have been operating, you know, sort of in absence of any federal regulations, and certainly haven’t been able to get this coveted GMP certification from Europe because, you know, you can only get GMP certification if your country actually has a federal framework. And because the US is absent on that and is still going to remain absent for quite some time on that, I think there’s a real opportunity for Canadian companies here to compete on the global scale.

Now keep in mind, you know, I don’t think the risk is necessarily the US or the threat is the US at this point; I’m paying very close attention to Israel. Israel was recently allowed to start to export medical cannabis, and you know, it’s something that has been stalled for very many years by their Parliament, but the government has finally given it approval. And a lot of the operators there, apparently, already have this coveted GMP certification, so for them to be able to export into the European markets is not going to be a significant challenge.

So you know, I don’t think the US is as much of a threat on the international side, but I certainly see countries like Israel and others that will get GMP sort of established being a threat to Canadian licensed producers.

Benjamin A. Smith: Wow, very interesting answer. Deepak, thank you so much for joining us on the program. We’ll talk to you soon.

Ed Milewski:  Thanks, Deepak.





Source link

What is CBD/ how does CBD oil work?



CBD Oil for Anxiety – UNEXPECTED Effects and Benefits – Duration: 9:47. Depression to Expression 293,544 views · 9:47. Play next; Play now.



Source link

America’s CBD boom: Brazen claims, fake products, regulatory scrutiny


Got arthritis? Dry skin? Menstrual cramps? Trouble sleeping or feeling stressed? The CBD industry claims it has the cure for you.

Such assertions are becoming increasingly common — and brazen — as the cannabis compound commonly known as CBD proliferates in drinks, baked goods, tinctures, body lotions and even bath salts. To some, the hype echoes 19th-century snake oil advertisements that promised to cure “all aches and pains!”

While CBD is generally believed to be safe, scant research has been conducted on its medical and health benefits because cannabis has long been prohibited at the federal level. The only clinically proven remedy is a treatment for two rare forms of childhood epilepsy. All other claims are anecdotal.

Now regulators are starting to pay closer attention. This month, New York health officials ordered bakeries and restaurants to stop adding cannabidiol, the formal name for CBD, to beverages and food. In December, the Food and Drug Administration made clear that it’s illegal to market CBD products as dietary supplements.

“Nobody’s been allowed to do the research for all these years, so it’s a big open space where companies can say things without the data to back it up,” said Kent Hutchison, co-director of the University of Colorado’s CU Change Lab.

CBD has been sold online for years, mostly to people already familiar with THC, the psychoactive sibling that gets you high. More recently, the legalization of marijuana in several states and the boom in wellness products have pushed CBD into the mainstream. Consumers are putting it under their tongues, rubbing it on their sore muscles and guzzling seltzer infused with the trendy ingredient. Retail sales of CBD more than quadrupled last year, according to the data firm SPINS, with most purchases taking place at natural grocery stores.

The stuff doesn’t come cheap: A bottle of oil with 1,500 milligrams of “full-spectrum hemp oil” sells for $160 on the new website Standard Dose. A California company called Good Bites sells bags of four CBD macaroons for $20, which gets you 100 milligrams. Populum, in Tempe, Ariz., sells a 1 fluid ounce bottle that contains 19 milligrams of CBD for $99. With prices like that, it’s easy to see why analysts expect the CBD market to be worth more than $20 billion by 2022, up from roughly $600 million now.

The growing demand for CBD dovetails with Americans’ longstanding appetite for super foods and ingredients that promote wellness. In a divided and anxious nation, moreover, many people are willing to try products that claim to ease insomnia and stress. CBD is following a path already traveled by turmeric, acai berries, ginkgo biloba and so on. People tell each other the stuff works, word travels and the cash registers keep ringing.

“America has always had a population looking for the silver bullet,” said Kara Nielsen, who tracks food trends at CCD Helmsman in California. “The hype follows a similar pattern: It has a lot going for it, but it’s unclear exactly what it does so it allows people to imagine it’s their solution.”

The decade-old boom in dietary supplements could be a harbinger of what happens next with CBD. Makers of supplements have long made dubious claims and drawn the ire of regulators. This month, the FDA issued 12 warning letters and five online advisories to foreign and domestic companies for selling products that claim to prevent, treat or cure Alzheimer’s, among other diseases and health conditions.

The FDA has adopted a fairly benign posture toward CBD — occasionally sending letters warning companies not to make unsubstantiated claims and reminding them that the chemical remained prohibited under the Controlled Substances Act. Then in December, Congress passed the farm bill, which makes the chemical compounds found in hemp, including CBD, legal under certain circumstances.

The legalization places hemp-derived CBD squarely under the authority of federal agencies including the FDA, which said in December that any CBD product marketed as having therapeutic benefits must be approved for its intended use before it’s introduced into interstate commerce.

Regulators are paying more attention at the state level as well. Besides New York, Maine and Ohio have cracked down on the sale of CBD as officials sort out the legal status of a substance that the FDA hasn’t approved as a food additive.

If the dietary supplement industry is any guide, the crackdown is unlikely to deter makers and purveyors of CBD products. So long as they keep their claims vague, they should be able to continue selling their products, especially ones that are applied externally and not ingested.

Dr. Yasmin Hurd, director of the Addiction Institute at Mount Sinai, has watched all the CBD hype with bemusement. She’s studied the substance for 10 years and thinks it could help treat opioid addiction. Her biggest fear is that the “commercialization” of CBD could prevent serious medical research on a drug that she thinks has immense potential.

The problem, in her eyes, is that there might not be funding for CBD studies if the product is already widely available.

“A lot of people are making money but they’re not willing to actually do the research,” she said. “Everyone is missing the more important point here.”

Apart from the epilepsy drug from GW Pharmaceuticals Plc, drug makers have so far adopted a wait-and-see position. If and when clinical trials have been completed, chances are good they’ll swoop in and acquire some of the leading marijuana companies.

The studies that have been done suggest CBD can help boost the immune system and reduce inflammation, but with one important caveat: those studies haven’t been done on humans. Existing research also indicates that 500 milligrams of CBD is required for it to be effective, a far higher dose than typically found in most consumer products. Meanwhile, with oversight lax, fake products containing no CBD whatsoever have proliferated, according to industry observers.

Joe Dowling runs CV Sciences, a publicly traded company that sells a top-selling oil called Plus CBD Oil that’s available in 2,000 stores around the country. Dowling said it’s “irritating” that unscrupulous companies are rushing into the market, making health claims and selling fake products. CV Sciences consults with attorneys who understand FDA rules, he said, and is deliberately vague about CBD’s benefits, calling the chemical a “key supplement to maintain a healthy lifestyle.”

Dowling welcomes more FDA oversight as well as clinical trials that will prove CBD’s benefits and provide a basis for more accurate marketing.

“It’s going to be the Wild West for a while,” he said.



Source link